Literature DB >> 15065636

Histogenesis of CD5-positive and CD5-negative B-cell neoplasms on the aspect of somatic mutation of immunoglobulin heavy chain gene variable region.

Naoya Nakamura1, Masafumi Abe.   

Abstract

The immunoglobulin heavy chain (IgH) gene of B-cells dramatically alters twice in their differentiation to memory or plasma cells; VDJ recombination at B-cell precursor and somatic hypermutation, class switch recombination and receptor revision at germinal center (GC) B-cells. Among them, somatic hypermutation of the IgH gene variable region (VH gene) is a powerful tool for detection of B cell differentiation. B-cells and B-cell neoplasms have been divided into following; 1) pre-GC B-cells and neoplasms with a germline VH gene and 2) GC and post-GC B-cells and neoplasms with a somatically mutated VH gene. In this article, we review normal B-cell differentiation and histogenesis of various types of B-cell neoplasms on the aspect of somatic mutation of the rearranged VH gene. In particular, differences between CD5+ and CD5- B-cell neoplasms, using our own data of over 100 cases with B-cell neoplasms, are discussed. Although CD5+ B-cells are included in pre-GC B-cells for the reason of germline VH gene in most of CD5+ B-cells, an about 5% of CD5+ B-cells show somatically mutated VH gene. The rearranged VH gene of CD5+ B-cell neoplasms shows heterogeneity, whereas CD5- B-cell neoplasms possess somatically mutated VH gene with a mean of 8 approximately 12%. Both CD5+ B-cell chronic lymphocytic leukemia and CD5+ diffuse large B-cell lymphoma display that about half of cases show a germline or low frequency of somatic mutation and the others possess somatically mutated VH gene. CD5+ mantle cell lymphoma constitutes most cases with germline and a small number of cases with mutated VH gene. Therefore, CD5- B-cells & CD5- B-cell neoplasms are distinct from CD5+ B-cells and CD5+ B-cell neoplasms in somatic mutation of VH gene. It suggests that each of CD5- and CD5+ B-cells independently has its own differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15065636     DOI: 10.5387/fms.49.55

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  3 in total

1.  CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region.

Authors:  Naoya Nakamura; Shigeo Nakamura; Motoko Yamaguchi; Ryo Ichinohasama; Tadashi Yoshino; Tetsuo Kuze; Yoshikazu Sasaki; Sachiko Yoshida; Masafumi Abe
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

2.  Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody.

Authors:  Naoya Nakamura; Hidenori Hase; Daisuke Sakurai; Sachiko Yoshida; Masafumi Abe; Nobuhiro Tsukada; Jun Takizawa; Sadao Aoki; Masaru Kojima; Shigeo Nakamura; Tetsuji Kobata
Journal:  Virchows Arch       Date:  2005-06-14       Impact factor: 4.064

3.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Authors:  Zijun Y Xu-Monette; Meifeng Tu; Kausar J Jabbar; Xin Cao; Alexandar Tzankov; Carol Visco; Lalitha Nagarajan; Qingqing Cai; Santiago Montes-Moreno; Yuji An; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Michael B Møller; John P Farnen; Jane N Winter; Miguel A Piris; Roberto N Miranda; L Jeffrey Medeiros; Ken H Young
Journal:  Oncotarget       Date:  2015-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.